The AeviceMD wearable stethoscope allows clinicians to track lung sounds and detect early signs of respiratory distress in children with asthma.
RT’s Three Key Takeaways:
- Remote Monitoring Technology: Cedars-Sinai Guerin Children’s is utilizing a wearable stethoscope to provide clinicians with continuous or on-demand remote monitoring of pediatric lung sounds.
- Early Intervention: The real-time data allows healthcare professionals to identify worsening symptoms between clinic visits, potentially reducing emergency department visits and systemic steroid use.
- Clinical Validation: The device, which received FDA clearance in 2023, was developed through a multiyear collaboration between Aevice Health and clinicians at Guerin Children’s.
Cedars-Sinai Guerin Children’s has launched a new program for children with asthma that utilizes a wearable stethoscope to track respiration and aid in the early detection of breathing problems, according to the organization. The program uses the AeviceMD device to provide healthcare professionals with continuous or on-demand remote monitoring of lung sounds.
The technology enables clinicians to monitor a child’s condition between clinic visits and respond early if symptoms worsen. Approximately 4.5 million children in the US have asthma, making it one of the most common chronic pediatric diseases. Traditionally, monitoring has relied on periodic clinic visits and caregiver reports of symptoms such as rapid breathing, chest congestion, and breathing difficulties, which can be unreliable.
“I saw strong potential in this technology to support how we monitor and manage children with reactive airway issues like asthma outside of the clinical setting,” said Irina Dralyuk, a pediatric pulmonologist at Guerin Children’s, in a news release. “Being able to assess respiratory symptoms in real time, especially overnight, provides valuable information that can guide earlier intervention and help prevent more serious breathing complications.”
The wearable device, which is about the size of a half-dollar coin, is worn on the chest for up to 10 hours a day. It is designed for use in children aged 3 and older. The device allows parents to record lung sounds at home and share those recordings securely with doctors. This data helps clinicians build a detailed picture of disease progression, track medication use, and assess how symptoms evolve in response to treatment plans.
“What we’re trying to do is prevent exacerbations, reduce hospitalizations and emergency department visits, and limit the need for interventions such as systemic steroid use to control asthma symptoms,” said Dralyuk, in a news release.
The AeviceMD device was developed by Aevice Health, a Singaporean digital health company, following a multiyear collaboration with Cedars-Sinai that began in 2022. The collaboration included clinical input from physicians at Guerin Children’s and a pilot program to evaluate the device’s effectiveness. The device received clearance from the FDA in 2023.
“We built AeviceMD to make this kind of continuous symptom visibility possible. Having our technology deployed at a large, world-class healthcare system like Cedars-Sinai validates our belief that there is a critical, unmet patient need,” said Adrian Ang, CEO of Aevice Health, in a news release.
Nirdesh K Gupta, PhD, managing partner of Cedars-Sinai Intellectual Property Company, noted that the collaboration highlights the importance of providing clinical and operational support to advance medical technology.
“It’s an exciting example of how innovation can directly impact care and improve the way we manage chronic conditions like asthma,” said Gupta.
